European regulators won ' t back Amgen/UCB drug

Amgen and Belgian partners at UCB announced that the EMA has adopted a negative opinion on Evenity, for the treatment of osteoporosis in men and in postmenopausal women at increased risk of fracture.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news